Counting the Cost of Daptomycin Versus Vancomycin in Hospitalized Patients: A Cost Minimization Analysis

Open Forum Infect Dis. 2024 Apr 18;11(5):ofae217. doi: 10.1093/ofid/ofae217. eCollection 2024 May.

Abstract

Daptomycin use for gram-positive infections has increased. This cost minimization analysis aimed to determine cost and/or time savings of daptomycin over vancomycin. The estimated hospital cost savings was US$166.41 per patient, and pharmacist time saved of almost 20 minutes per patient. Daptomycin has the potential to save both time and money.

Keywords: bacterial infection; cost analyses; daptomycin; gram-positive; vancomycin.